Transdermal estrogen spray in therapy of postmenopausal syndrome

Authors: T. Fait 1,2
Authors‘ workplace: Česká menopauzální a andropauzální společnost ČLS JEP, předseda doc. MUDr. T. Fait, Ph. D. 1;  Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha, přednosta prof. MUDr. A. Martan, DrSc. 2
Published in: Ceska Gynekol 2016; 81(1): 77-80


To show possibilities of new application method of estrogen replacement therapy – mettered-dose transdermal spray.

Review article

Transdermal spray contains 1.53 mg estradiol in one dose. It gives possibility of individual aproach in estradiol application 1, 2 or 3 doses daily. About 85% of patients showed the significant reduction of hot flushes. Perfect safety profile is predicted especially in cardiovascular point.

mettered-dose transdermal spray, hormone replacement therapy, perimenopausal symptoms, tromboembolic desease


1. Acher, D. Menopausal hot flashes are treated effectively by a transdermal, low dose estradiol spray. Nature Rev Endocrinol, 2009, 5, p. 18–19.

2. Beral, V., Banks, E., Reeves, G. Evidence from randomised trials on the long-term effects of HRT. Lancet, 2002, 360, p. 942–944.

3. Birkhauser, MH., Barlow, DH., Notelovitz, M., et al. Health plan for the adult woman. Taylor and Francis, 2005, p. 248.

4. Buster, JE. Low-dose estradiol spray: a novel treatment for vasomotor instability in postmenopausal women. Womens Health, 2009, 5(1), p. 23–28.

5 Buster, JE., Koltun, WD., Pascual, ML., et al. Low-dose estradiol spray to treat vasomotor symptoms: a randomize controlled trial. Obstet Gynecol, 2008, 111(6), p. 1343–1351.

6. Derzko, C., Sergerie, M., Siliman, G., et al. Comparative efficacy and safety of estradiol transdermal preparations for the treat­ment of vasomotor symptoms in postmenopausal women: an indirect comparison meta-analysis. Menopause 2015, Nov 4 [Epub ahead of print].

7. Egas, AM., Umland, EM. The role of trandermal estrogen sprays and estradiol topical emulsion in the management of menopause – associated vasomotor symptoms. Int J General Med, 2010, 3, p. 147–151.

8. Fait, T., Donát, J., Jeniček, J., a kol. Doporučení pro hormonální substituční terapii v postmenopauze. Čes Gynek, 2010, 75, 2, s. 109–110.

9. Fait, T., Vrablik, M. Coronary heart disease and hormone replacement therapy – from primary and secondary prevention to the window of opportunity. Neuro Endocrinol Lett, 2012, 33, Suppl. 2, p.17–21.

10. Hillard, TC., Whitcroft, SJ., Marsh, MS., et al. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporosis, 1994, 4, p. 341–348.

11. Hoibraaten, E., Qvigstad, E., Amesen, H., et al. Increased risk in recurrent venous tromboembolism during HRT – results of the randomized, double-blind, placebo-controlled estrogen in venous tromboembolism trial (EVTET). Tromb Haemost, 2000, 84, p. 961–966.

12.Hulley, S., Grady, D., Bush, M. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart desease in postmenopausal women. JAMA, 1998, 280, p. 605–613.

13. Ibarra de Palacios, P., Schmidt, G., Sergejew, T., et al. Comparative study to evaluate skin irritation and adhesion of Estradot and Climara in healthy postmenopausal women. Climacteric, 2002, 5(4), p. 383–389.

14. Ibrahim, SA. Spray-on transdermal drug delivery systems. Expert Opin Drug Delivery, 2015, 12(2), p. 195–205.

15. Lowe, G., Woodward, M., Vessey, M., et al. Trombotic variables and risk of idiopathic venous thromboembolism in women aged 45–64 years. Relationships to HRT. Thromb Haemostat, 2000, 83 (4), p. 530–535.

16. MacLennan, AH., Broadbent, JL., Lester, S., Moore, V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev, 2004, 4, CD 002978.

17. Morton, TL., Gattermeir, DJ., Petersen, CA., et al. Steady state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women. J Clin Pharmacol, 2009, 49(9), p. 1037–1046.

18. Place, VA., Powers, M., Darley, PE., et al. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol, 1985, 152( 8), p. 1092–1099.

19. Renaus, C., Dell´Aniello, S., Garbe, E., Suissa, S. HRT use and the risk of stroke. Mauritas, 2008, 61, p. 305–309.

20.Scarabin, PY., Oger, E., Plu-Bureau, G. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet, 2003, 36, p. 428–432.

21. Schumacher, RJ., Gattermeir, DJ., Peterson, CA., et al. The effects of skin-to-skin contact, application site washing, and sunscreen use on the pharmacokinetics of estradiol from a metered-dose transdermal spray. Menopause, 2009, 16(1), p. 177–183.

22. Stanczyk, FZ., Shoupe, D., Nunez, V., et al. A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol, 1988, 159(6), p. 1540–1546.

23. Straczek, C., Oger, E., Yon de Jonage-Canonico, MB., et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation, 2005, 112, 22, p. 3495–3500.

24. Vrablik, M., Fait, T., Kovar, J., et al. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. Metabolism, 2008, 57(8), p. 1088–1092.

25. WHI Steering Commitee. Effect of CEE in postmenopausal women. JAMA, 2004, 291, p. 1701–171.2

26. Wu, O. Postmenopausal HRT and venous tromboembolism. Gen Med, 2005, 2, Suppl. A, p. 18–27.

Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine

Article was published in

Czech Gynaecology

Issue 1

2016 Issue 1

Most read in this issue
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account